Pfizer has decided to abandon the development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, potentially impacting Sangamo’s future. This decision comes as a surprise, as Pfizer had previously indicated its intention to bring the treatment to regulators. However, the approval of another gene therapy for the same disorder last year has limited interest in new treatments, as the current standard of care is already effective. Sangamo’s leadership was relying on this treatment to help revive the struggling biotech company, as Pfizer still owed them $220 million in milestones as per their 2017 agreement.
Source link
Pfizer drops hemophilia gene therapy, imperiling partner Sangamo
